Dopamine supersensitivity psychosis as a pivotal factor in treatment-resistant schizophrenia

Psychiatry Research

Volumn 227, Issue 2-3, 2015, Pages 278-282

  Suzuki, Tomotaka ^a,b   Kanahara, Nobuhisa ^a   Yamanaka, Hiroshi ^a,c   Takase, Masayuki ^a   Kimura, Hiroshi ^a   Watanabe, Hiroyuki ^a   Iyo, Masaomi ^a  

^a CHIBA UNIVERSITY   (Japan)

^b Koutokukai   (Japan)

^c Chiba Psychiatric Medical Center   (Japan)

Author keywords

Antipsychotics; Clinical course; Deficit syndrome; Dopamine D2 receptor; Prognosis; Tardive dyskinesia; Treatment resistant

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; DOPAMINE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DOPAMINE SUPERSENSITIVITY PSYCHOSIS; DRUG INDUCED DISEASE; FEMALE; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEDICAL RECORD REVIEW; MOTOR DYSFUNCTION; PATIENT CODING; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; PSYCHOSIS; SCHIZOPHRENIA; TREATMENT RESISTANT SCHIZOPHRENIA; DRUG TOLERANCE; MIDDLE AGED; MOVEMENT DISORDERS; PSYCHOSES, SUBSTANCE-INDUCED;

ADULT; ANTIPSYCHOTIC AGENTS; DOPAMINE; DRUG TOLERANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; MOVEMENT DISORDERS; PSYCHOSES, SUBSTANCE-INDUCED; SCHIZOPHRENIA;

EID: 84929130040     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2015.02.021     Document Type: Article

References (33)

1. Andreasen N.C. Scale for the Assessment of Negative Symptoms (SANS) 1984, University of Iowa, Iowa City.
2. Andreasen N.C., Carpenter W.T., Kane J.M., Lasser R.A., Marder S.R., Weinberger D.R. Remission in schizophrenia: proposed criteria and rationale for consensus. American Journal of Psychiatry 2005, 162:441-449.
3. Bertelsen M., Jeppesen P., Petersen L., Thorup A., Øhlenschlaeger J., Le Quach P., Østergaard Christensen T., Krarup G., Jørgensen P., Nordentoft M. Course of illness in a sample of 265 patients with first-episode psychosis-five-year follow-up of the Danish OPUS trial. Schizophrenia Research 2009, 107:173-178.
4. Brenner H.D., Dencker S.J., Goldstein M.J., Hubbard J.W., Keegan D.L., Kruger G., Kulhanek F., Liberman R.P., Malm U., Midha K.K. Defining treatment refractoriness in schizophrenia. Schizophrenia Bulletin 1990, 16:551-561.
5. Carpenter W.T., Heinrichs D.W., Wagman A.M. Deficit and nondeficit forms of schizophrenia: the concept. American Journal of Psychiatry 1988, 145:578-583.
6. Chakos M., Lieberman J., Hoffman E., Bradford D., Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. American Journal of Psychiatry 2001, 158:518-526.
7. Chouinard G., Jones B.D., Annable L. Neuroleptic-induced supersensitivity psychosis. American Journal of Psychiatry 1978, 135:1409-1410.
8. Chouinard G., Annable L., Ross-Chouinard A., Mercier P. A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases. Journal of Clinical Psychopharmacology 1988, 8:21S-26S.
9. Chouinard G. Severe cases of neuroleptic-induced supersensitivity psychosis. Diagnostic criteria for the disorder and its treatment. Schizophrenia Research 1991, 5:21-33.
10. Chouinard G., Chouinard V.A. Atypical Antipsychotics. CATIE Study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes. Psychotherapy and Psychosomatics 2008, 77:69-77.
11. Cohen A.S., Brown L.A., Minor K.S. The psychiatric symptomatology of deficit schizophrenia: a meta-analysis. Schizophrenia Research 2010, 118:122-127.
12. Evensen J., Røssberg J.I., Barder H., Haahr U., Hegelstad W.t., Joa I., Johannessen J.O., Larsen T.K., Melle I., Opjordsmoen S., Rund B.R., Simonsen E., Sundet K., Vaglum P., Friis S., McGlashan T. Apathy in first episode psychosis patients: a ten year longitudinal follow-up study. Schizophrenia Research 2012, 136:19-24.
13. Fenton W.S., McGlashan T.H., Victor B.J. Antecedents, symptom, progression, and long-term outcome of the deficit syndrome in schizophrenia. American Journal of Psychiatry 1994, 151:351-356.
14. Gardos G., Cole J.O., Tarsy D. Withdrawal syndromes associated with antipsychotic drugs. American Journal of Psychiatry 1978, 135:1321-1324.
15. Henna Neto J., Elkis H. Clinical aspects of super-refractory schizophrenia: a 6-month cohort observational study. Revista Brasileira de Psiquiatria 2007, 29:228-232.
16. Inada T. Recent research trends in diagnosis, treatment, and prevention of drug-induced extrapyramidal symptoms seen in psychiatric patients. Nihon Shinkei Seishin Yakurigaku Zasshi 1996, 16:181-185. (in Japanese).
17. Iyo M., Tadokoro S., Kanahara N., Hashimoto T., Niitsu T., Watanabe H., Hashimoto K. Optimal extent of dopamine D2 receptor occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis. Journal of Clinical Psychopharmacology 2013, 33:398-404.
18. Juarez-Reyes M.G., Shumway M., Battle C., Bacchetti P., Hansen M.S., Hargreaves W.A. Clozapine eligibility: the effect of stringent criteria on ethnic, gender and age subgroups of schizophrenic patients. Progress in Neuropsychopharmacology and Biological Psychiatry 1996, 20:1341-1352.
19. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of General Psychiatry 1988, 45:789-796.
20. Kaneda Y., Ohmori T., Addington D. The Japanese version of the calgary depression scale for schizophrenics (JCDSS). No To Shinkei 2000, 52:163-166. (in Japanese).
21. Kimura H., Kanahara N., Watanabe H., Iyo M. Potential treatment strategy of risperidone long-acting injectable form for schizophrenia with dopamine supersensitivity psychosis. Schizophrenia Research 2013, 145:130-131.
22. Kimura H., Kanahara N., Komatsu N., Ishige M., Muneoka K., Yoshimura M., Yamanaka H., Suzuki T., Komatsu H., Sasaki T., Hashimoto T., Hasegawa T., Shiina A., Ishikawa M., Sekine Y., Shiraishi T., Watanabe H., Shimizu E., Hashimoto K., Iyo M. A prospective comparative study of risperidone long-acting injectable for treatment-resistant schizophrenia with dopamine supersensitivity psychosis. Schizophrenia Research 2014, 155:52-58.
23. Kirkpatrick B., Buchanan R.W., McKenney P.D., Alphs L.D., Carpenter W.T. The schedule for the deficit syndrome: an instrument for research in schizophrenia. Psychiatry Research 1989, 30:119-123.
24. Kolalowska T. Brief Psychiatric Rating Scale. Glossaries and Rating Instructions 1976, Oxford University, Oxford.
25. Masand P.S., Roca M., Turner M.S., Kane J.M. Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review. Primary Care Companion to Journal of Clinical Psychiatry 2009, 11:147-154.
26. Moncrieff J. Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersenstivity psychosis) and withdrawal-related relapse. Acta Psychiatrica Scandinavica 2006, 114:3-13.
27. Seeman P., Weinshenker D., Quirion R., Srivastava L., Bhardwaj S.K., Grandy D.K., Premont R., Sotnikova T., Boksa P., El-Ghundi M., O'dowd B.F., George S.R., Perreault M.L., Mannisto P.T., Robinson S., Palmiter R.D., Tallerico T. Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis. Proceedings of the National Academy of Science United States of America 2005, 102:3513-3518.
28. Seeman P., Schwarz J., Chen J.F., Szechtman H., Perreault M., McKnight G.S., Roder J.C., Quirion R., Boksa P., Srivastava L.K., Yanai K., Weinshenker D., Sumiyoshi T. Psychosis pathways converge via D2high dopamine receptors. Synapse 2006, 60:319-346.
29. Seeman M.V., Seeman P. Is schizophrenia a dopamine supersensitivity psychotic reaction?. Progress in Neuropsychopharmacology and Biological Psychiatry 2013, 48C:155-160.
30. Sim K., Su A., Fujii S., Yang S.Y., Chong M.Y., Ungvari G.S., Si T., Chung E.K., Tsang H.Y., Chan Y.H., Heckers S., Shinfuku N., Tan C.H. Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia. British Journal of Clinical Pharmacology 2004, 58:178-183.
31. Strauss G.P., Harrow M., Grossman L.S., Rosen C. Periods of recovery in deficit syndrome schizophrenia: a 20-year multi-follow-up longitudinal study. Schizophrenia Bulletin 2010, 36:788-799.
32. Tek C., Kirkpatrick B., Buchanan R.W. A five-year followup study of deficit and nondeficit schizophrenia. Schizophrenia Research 2001, 49:253-260.
33. Zigmond A.S., Snaith R.P. The hospital anxiety and depression scale. Acta Psychiatrica Scandinavica 1983, 67:361-370.